Posts by Kathleen E. Corey, MD, MPH, MMSc
-
Tobacco Use and Type 2 Diabetes Have Additive Effect on Risk of Fibrosis in Patients With MASLD
Oluwafemi Balogun, MBBS, MPH, Kathleen E. Corey, MD, MPH, MMSc, and colleagues demonstrated that smoking and underlying type 2 diabetes mellitus (T2DM) have a synergistic effect on the severity of fibrosis, nearly doubling the risk (OR, 1.88; P=0.0037) compared with nonsmokers who do not have T2DM.
-
Medical Grand Rounds: Updates in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma
In a Medical Grand Rounds presentation, Kathleen Corey, MD, MPH, MMSc, and Tracey Simon, MD, MPH, of the Division of Gastroenterology at Massachusetts General Hospital, presented on the assessment of non-alcoholic fatty liver disease and the prevention of hepatocellular carcinoma.
-
Risk Factors Identified for Cardiovascular Disease in Individuals With Hepatic Steatosis
Kathleen E. Corey, MD, MPH, MMSc, Júlia Karády, MD, and colleagues conducted the first study of risk factors for cardiovascular disease risk in patients with hepatitis steatosis based on comprehensive baseline profiling as well as prospective analysis of major adverse cardiovascular events.
-
Cardiovascular Disease Independently Associated with NAFLD in People with HIV
Cardiovascular disease, higher body mass index and CD4 count <200 cells/mm3 were significantly associated with nonalcoholic fatty liver disease among adults with HIV, even after adjustment for traditional cardiovascular disease risk factors.
-
Advanced Fibrosis Predicts Nonfatal CVD in NAFLD Patients
Advanced fibrosis accounts for two-thirds of the risk of new-onset cardiovascular disease in patients with nonalcoholic fatty liver disease.
-
Intermittent Fasting: Prescribed Nutritional Intervention
Massachusetts General Hospital physicians have introduced a protocol-based intermittent fasting intervention and are beginning a study to determine fasting's impact on liver fat.
-
Daily Aspirin Use Tied to Lower Risk of Fibrosis Progression in Nonalcoholic Fatty Liver Disease
Long-term data from a prospective cohort of patients with nonalcoholic fatty liver disease, who reported their aspirin use regularly, provides evidence of hepatoprotective effects of daily aspirin.
Biography
Kathleen E Corey, MD, MPH, MMSc is an Associate Professor of Medicine at Harvard Medical School and Director of the Fatty Liver Clinic in the Mass General Gastrointestinal Unit.
Dr. Corey's clinical interests include all areas of hepatology including non-alcoholic fatty liver disease (NAFLD), viral hepatitis including hepatitis B, C and D infection, autoimmune hepatitis, cholestatic liver disease including primary biliary cirrhosis and primary sclerosing cholangitis. In addition, Dr. Corey treats patients with hereditary forms of liver disease including hemochromatosis and alpha-1-antitrypsin disease. Dr. Corey is also a transplant hepatologist and evaluates patients in need of liver transplantation and cares for patients after liver transplant. Dr. Corey also performs endoscopies including diagnostic and therapeutic upper endoscopy and colonoscopy.
Dr. Corey's research focuses on non-alcoholic fatty liver disease and the development of non-invasive biomarkers for the diagnosis and monitoring of NAFLD. Dr. Corey has lectured regionally and nationally on NAFLD
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.